Patent thicket strategy with terminal disclaimers helps block biologic competition, JAMA letter shows
15 Dec 2023
Patent Expiration
Biologics developers are protecting their most lucrative assets with a particular type of patent that they can quickly pile up and drive costly litigation around, preventing competitive biosimilars from coming to the US quickly, according to a new
JAMA
research letter.
The research points to so-called “terminal disclaimer” patents. The patents expire at the same time as the original patent and can be applied late in a biologic’s exclusivity period, but allow manufacturers to quickly build a fortress of patents around trivial changes. That “can trigger lengthy and costly litigation and add uncertainty for biosimilar manufacturers who must invalidate or design around all patents in a biologic’s portfolio,” said the researchers from the West Virginia University College of Law, Fresenius Kabi USA, and Harvard.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.